Vertex Pharmaceuticals Incorporated today announced that Peter Mueller, Ph.D., Executive Vice President of Global Research and Development and Chief Scientific Officer, will retire after more than 10 years with the company. Dr. Mueller's retirement will be effective October 31, 2014, following a planned transition period. Dr. Mueller joined Vertex in 2003 as Chief Scientific Officer and Senior Vice President, Drug Discovery and Innovation.
"Peter is a visionary who embodied Vertex's fearless pursuit of transformational medicines," said Jeffrey Leiden, M.D., Ph.D., Chairman, President and Chief Executive Officer of Vertex. "I thank Peter for his leadership, innovation and dedication to Vertex over the past decade."
Jeffrey A. Chodakewitz, M.D., Vertex's Senior Vice President of Global Medicines Development and Medical Affairs and Chief Medical Officer, will continue to oversee all global clinical development programs and other related functions and will now assume additional responsibility for Regulatory Affairs and Global Patient Safety. Vertex expects to appoint a Head of Global Research to oversee the company's drug discovery efforts following Dr. Mueller's retirement.